Restrictions for patents owners to preserve the public interest in the sufficient availability of necessary medicinal products
GDPR and life sciences – part 2
The Bolar and related exemptions in Europe
What activity do they cover?
by multiple authors
Falsified Medicine Directive continued: Safety features on medicinal products and its consequences
GDPR and private sector life sciences
by Debbie Heywood and Sally Annereau
Biosimilars – The economics of biosimilars: Market access, pricing and legal considerations
SPC manufacturing waiver (Part 2): The fairy tale of day-1 entry under the manufacturing and stockpiling waiver – a German view
Patenting of gene and protein sequences: an EU and US perspective
First Dutch GDPR fine for failing to ensure security of patient files
Dr Bill Frankland: Penicillin, the pollen count and perspectives on medicine